Bipolar Disorder, Schizophrenia
Conditions
Keywords
Schizophrenia, probiotics, cognitive impairment, Metabolic syndrome, clinical trail, Efficacy, Safety, Dietary fiber, Bipolar Disorder
Brief summary
In this study, the investigators will evaluate the efficacy, safety and related mechanism of dietary fiber and probiotics alone and in combination as a add-on treatment in improving the antipsychotic induced weight gain, the cognitive impairment, and psychotic syndrome in schizophrenia or bipolar disorder patients. The study will recruit 100 schizophrenia or bipolar disorder patients who meet the criteria of DSM-5, and then randomized to 4 groups: probiotics group(PB group) dietary fiber group(FB group) probiotics plus dietary fiber group(PF group) and control group(CT group) for a 12-weeks clinical trail. The specific aims are to compare probiotics group versus controls on: 1) clinical core symptoms; 2) cognition;3)metabolic related markers.
Detailed description
In this study, the investigators will evaluate the efficacy, safety and related mechanism of dietary fiber and probiotics alone and in combination as a add-on treatment in improving the antipsychotic induced weight gain, the cognitive impairment, and psychotic syndrome in schizophrenia or bipolar disorder patients. The study will recruit 100 schizophrenia or bipolar disorder patients who meet the criteria of DSM-5, and then randomized to 4 groups: probiotics group(PB group) dietary fiber group(FB group) probiotics plus dietary fiber group(PF group) and control group(CT group) for a 12-weeks clinical trail (20 patients per arm) for a 12-weeks clinical trail. Clinical efficacy and safety assessment will be done at screen/baseline, 4 week, 8 week and 12 week. The specific aims are to compare probiotics group versus controls on: 1) clinical core symptoms; 2) cognition; 3) metabolic related markers. Biological samples also will be collected, and stored to research related mechanisms. Clinical symptoms will be measured by the Positive and Negative Syndrome Scale,. Cognitive function will be assessed by the MATRICS Consensus Cognitive Battery. The investigators hypothesize that: 1) dietary fiber and probiotics may improve cognitive impairment of patients with schizophrenia; 2) dietary fiber and probiotics could prevent the cognitive decline of patients with schizophrenia; 3)dietary fiber and probiotics may prevent the antipsychotics induced weight gain in patients with schizophrenia.4)dietary fiber and probiotics may alter oxidative stress indexes or inflammatory biomarkers thus influence the oxidative and inflammatory mechanism.
Interventions
DRUGBifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)
Bifico 840mg Bid
DIETARY_SUPPLEMENTDietary fiber
dietary fiber compound powder 30g bid
Sponsors
Central South University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Meet the Diagnostic and Statistical Manual (DSM-V) diagnostic criteria for schizophrenia or bipolar disorder; 2. Patients with a weight gain of more than 10% after taking antipsychotic medications; 3. Male and female with aged 18 to 65 years; 4. PANSS total score \< 60 or HAMD-17 total score≤ 7 and YMRS total score\<5; 5. Signed the study consent for participation; 6. Not allergy to probiotics or dietary fiber medicine 7. On stable medication and dosage for at least 3 months.
Exclusion criteria
1. Having history of substance dependence or abuse or whose symptoms are caused by the other diagnosable mental disorders; 2. Having history of traumatic brain injury, seizures or other known neurological or organic diseases of the central nervous system; 3. Taking antidepressants, stimulants, mood stabilizer or accepts electricity shock treatment; 4. Having current suicidal or homicidal thoughts or any safety concern by research staff that cannot be manage in an inpatient setting; 5. The routine blood tests showing abnormal renal, liver function; 6. Pregnant or lactating women. 7. No administration of any antibiotics in two mouths
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MATRICS Consensus Cognitive Battery (MCCB) composite score | 12 weeks | The investigators will use the MATRICS Consensus Cognitive Battery (MCCB) Composite score as primary cognitive outcome measure before and after treatment at different follow up point. |
| Body Mass Index | 12 weeks | The body mass index (BMI) or Quetelet index is a value derived from the mass (weight) and height of an individual. The BMI is defined as the body mass divided by the square of the body height, and is universally expressed in units of kg/m2, resulting from mass in kilograms and height in metres. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Positive And Negative Syndrome Scale (PANSS) | 12 weeks | The change of Positive And Negative Syndrome Scale (PANSS) total, positive and negative symptoms before and after treatment at different follow up point. |
| Lipid metabolism related blood index | 12 weeks | Other lipid metabolism related marker such as LDL,HDL,TG, CHO (all in mmol/L) |
| Physical exam index | 12 weeks | Body weight related physical exam index: waist circumference,hip line (cm) |
| Hamilton Depression Scale and Young Manic Rating Scale (YMRS) | 12 weeks | The change of total score of the Hamilton Depression Scale and the Young Manic Rating Scale (YMRS), used to measure mania and depression symptoms of bipolar disorder. |
Countries
China
Outcome results
None listed